Valuation: Acrux Limited

Market Cap 6.16M 4.32M 3.76M 3.5M 3.21M 6.07M 413M 41.23M 16.18M 205M 16.24M 15.88M 689M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.27M 5.45M 5.07M 4.66M 8.79M 598M 59.79M 23.47M 298M 23.54M 23.03M 999M EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 week-16.67%
1 month-23.08%
3 months-16.67%
6 months-33.33%
Current year-33.33%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.78
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-16.67%-41.18%-79.59% 3.6M
-0.53%+2.54%+22.14%+74.08% 50.03B
-1.81%-0.49%+48.83%+107.71% 36.6B
+0.46%+4.44%-1.97%+25.02% 12.47B
+1.05%+1.63%+18.73%+77.76% 11.77B
-1.33%-0.76%+30.73%+127.63% 9.04B
-2.99%-2.09%+45.28%-11.87% 7.03B
+0.51%+1.46%+13.46%+32.06% 6.79B
+1.99%+1.91%+8.03%+183.42% 6.6B
+0.39%+3.39%-35.25%+4.49% 5.49B
Average -0.23%-0.80%+10.88%+54.07% 14.58B
Weighted average by Cap. -0.61%+1.27%+24.94%+78.17%

Financials

2024 2025
Net sales 5.09M 3.57M 3.11M 2.89M 2.65M 5.01M 341M 34.08M 13.38M 170M 13.42M 13.13M 569M 1.19M 835K 726K 676K 621K 1.17M 79.74M 7.97M 3.13M 39.7M 3.14M 3.07M 133M
Net income -5.8M -4.07M -3.54M -3.29M -3.02M -5.71M -389M -38.83M -15.24M -193M -15.29M -14.95M -649M -5.94M -4.17M -3.63M -3.38M -3.1M -5.85M -398M -39.8M -15.62M -198M -15.67M -15.33M -665M
Net Debt 759K 533K 463K 431K 396K 747K 50.86M 5.08M 1.99M 25.32M 2M 1.96M 84.9M 2.77M 1.95M 1.69M 1.57M 1.45M 2.73M 186M 18.56M 7.28M 92.47M 7.31M 7.15M 310M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
31/07/26 A$0.0100 -.--% 62,766
30/07/26 A$0.0100 -9.09% 3,698,957
29/07/26 A$0.0110 -.--% 1,429,995
28/07/26 A$0.0110 -.--% 2,638,948
27/07/26 A$0.0110 -8.33% 169,956

Annual profits - Rate of surprise